Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) gapped up before the market opened on Tuesday . The stock had previously closed at $8.96, but opened at $10.03. Intellia Therapeutics shares last traded at $9.89, with a volume of 2,272,951 shares traded.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on NTLA shares. Wedbush reaffirmed a "neutral" rating and set a $7.00 price target on shares of Intellia Therapeutics in a report on Monday. Wells Fargo & Company decreased their price target on shares of Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. Wolfe Research upgraded shares of Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 target price on the stock in a research note on Monday, April 21st. Guggenheim cut their price objective on Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating on the stock in a research note on Monday, May 12th. Finally, JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $13.00 target price (down previously from $45.00) on shares of Intellia Therapeutics in a research report on Friday, February 28th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Intellia Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $34.95.
Get Our Latest Stock Analysis on NTLA
Intellia Therapeutics Stock Down 4.2%
The firm has a market cap of $952.94 million, a price-to-earnings ratio of -1.76 and a beta of 2.14. The stock's 50 day moving average is $8.30 and its 200 day moving average is $9.70.
Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($1.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $0.16. Intellia Therapeutics had a negative net margin of 1,154.10% and a negative return on equity of 56.06%. The company had revenue of $16.63 million for the quarter, compared to analysts' expectations of $11.39 million. During the same quarter in the previous year, the company posted ($1.12) EPS. The business's revenue was down 42.6% compared to the same quarter last year. Analysts anticipate that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of NTLA. Regeneron Pharmaceuticals Inc. acquired a new position in shares of Intellia Therapeutics in the 4th quarter worth $43,177,000. Voloridge Investment Management LLC lifted its holdings in shares of Intellia Therapeutics by 226.8% during the fourth quarter. Voloridge Investment Management LLC now owns 1,526,994 shares of the company's stock valued at $17,805,000 after purchasing an additional 1,059,751 shares during the last quarter. Contrarius Group Holdings Ltd acquired a new position in shares of Intellia Therapeutics in the 4th quarter valued at $11,798,000. Two Sigma Advisers LP increased its stake in Intellia Therapeutics by 94.5% in the 4th quarter. Two Sigma Advisers LP now owns 1,998,317 shares of the company's stock worth $23,300,000 after purchasing an additional 970,700 shares in the last quarter. Finally, Two Sigma Investments LP increased its stake in Intellia Therapeutics by 88.1% in the 4th quarter. Two Sigma Investments LP now owns 1,843,743 shares of the company's stock worth $21,498,000 after purchasing an additional 863,363 shares in the last quarter. Institutional investors own 88.77% of the company's stock.
Intellia Therapeutics Company Profile
(
Get Free Report)
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
Featured Stories
Before you consider Intellia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.
While Intellia Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.